Modern Healthcare (complimentary online subscription): An expert panel on Wednesday recommended the nasal form of the influenza vaccine should not be used for the upcoming flu season due to its lack of effectiveness over the past three years. Manufacturer AstraZeneca, which generated more than $200 million in sales of FluMist in fiscal year 2015, will take a financial hit.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now